Formulation of novel niosomal repaglinide chewable tablets using coprocessed excipients: in vitro characterization, optimization and enhanced hypoglycemic activity in rats
AbstractRepaglinide (RPG), a monotherapy insulin secretagogue used to treat diabetes mellitus-type II yet, it suffers from poor water solubility and variable bioavailability (∼ 50%) due to hepatic first pass metabolism. In this study, 2FI I-Optimal statistical design was employed to encapsulate RPG...
Main Authors: | Shahinaze A. Fouad, Mahmoud H. Teaima, Mostafa I. Gebril, Fathy I. Abd Allah, Mohamed A. El-Nabarawi, Sammar Fathy Elhabal |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2023-12-01
|
Series: | Drug Delivery |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/10717544.2023.2181747 |
Similar Items
-
The Impact of Surfactant Composition and Surface Charge of Niosomes on the Oral Absorption of Repaglinide as a BCS II Model Drug
by: Yaghoobian M, et al.
Published: (2020-11-01) -
Formulation of Chewable Tablets Containing Carbamazepine-β-cyclodextrin Inclusion Complex and F-Melt Disintegration Excipient. The Mathematical Modeling of the Release Kinetics of Carbamazepine
by: Adina Magdalena Musuc, et al.
Published: (2021-06-01) -
Formulation and Characterization of Acetazolamide/Carvedilol Niosomal Gel for Glaucoma Treatment: In Vitro, and In Vivo Study
by: Rehab Abdelmonem, et al.
Published: (2021-02-01) -
Reduction in glucose fluctuations in elderly patients with type 2 diabetes using repaglinide: A randomized controlled trial of repaglinide vs sulfonylurea
by: Kazuno Omori, et al.
Published: (2019-03-01) -
CONCEPTUAL RESEARCH ON THE TERM FACILITATION: REDUCING AN ELEPHANT TO CHEWABLE CHUNKS
by: Rinie Schenck, et al.
Published: (2008-10-01)